Efficacy and Safety of Paclitaxel and Carboplatin for Platinum-Sensitive Ovarian Cancer: A Systematic Review and Meta-Analysis

Table 1

Brief description of included studies.

Study year	Treatment regimen		Age (mean, range)
	CD	CP	CD	CP
L. Gladieff, 2012	161	183	60.0 (24∼82)	60.0 (30∼80)
U Wagner, 2012	466	509	60.5 (24∼82)	61.0 (27∼82)
Dimitrios Bafaloukos, 2010	93	96	63.0 (37∼81)	62.0 (38∼89)
Eric Pujade-Lauraine, 2010	466	507	60.5 (24∼82)	61.0 (27∼82)
Sven Mahner, 2014	131	128	60.0 (30∼80)	63.0 (27∼82)

CD: carboplatin-pegylated liposomal doxorubicin; CP: carboplatin-paclitaxel.